Compass Rose Asset Management LP acquired a new stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 420,000 shares of the biopharmaceutical company’s stock, valued at approximately $21,550,000. Bristol-Myers Squibb makes up approximately 9.0% of […]
Compass Rose Asset Management LP acquired a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the fourth quarter, HoldingsChannel reports. The firm acquired 420,000 shares of the biopharmaceutical company’s stock, valued at approximately $21,550,000. Bristol-Myers Squibb comprises about 9.0% of Compass Rose Asset Management LP’s holdings, making the stock its 4th largest position. […]
Bollard Group LLC cut its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 19.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 125,977 shares of the biopharmaceutical company’s stock after selling 31,232 shares during the period. Bollard Group LLC’s holdings in […]
Bollard Group LLC cut its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 19.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 125,977 shares of the biopharmaceutical company’s stock after selling 31,232 shares during the period. Bollard Group LLC’s holdings in […]
Tower Research Capital LLC TRC grew its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 319.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 278,314 shares of the biopharmaceutical company’s stock after purchasing an additional 211,949 shares during the period. Tower Research […]